Route Scouting For A Cost-Effective Process Development

Drug developers are facing increased pressure to accelerate timelines and go to market. These time and budget constraints often cause early development phases such as process development to be undervalued, placing projects at risk. Inefficient research processes can lead to longer production times for initial clinical supply, risk of failed batches, or costly delays.

Thermo Fisher Scientific’s Chemical Process Research Group (CPR Group) performs specifically early process research on new routes with dedicated analytical equipment and resources. Optimizing routes early in the development is crucial to ensure robust processes and mitigate potential risks. Learn how an experienced partner with 50 years of process development and manufacturing experience and an extensive track record of delivering new or optimized routes can help guide your project toward commercialization.